RxDoctor Payments Data

Robert Levy, MD

Ophthalmology · Salem, MANPI 1881692887

Payments from drug & device makers

$49,117in general payments, 2019–2025

Across 22 payments — averaging $2232.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$49K
  • Sun Pharmaceutical Industries Inc.$152
  • Tarsus Pharmaceuticals, Inc.$74
  • Novartis$67
  • Aerie Pharmaceuticals, Inc.$63
  • Alcon$63
  • plus $144 from 6 others

What the payments were for

  • Food & beverage$563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$49,117 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$457,954
Medicare patients
1,600
Services billed
4,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$25,442
Timolol Maleate225$14,713
Prednisolone Acetate220$14,308
Latanoprost1,335$14,195
LumiganBimatoprost33$13,815
Travoprost89$13,466
RocklatanNetarsudil Mesylat/Latanoprost17$9,623
Restasis MultidoseCyclosporine16$8,729
SimbrinzaBrinzolamide/Brimonidine Tart30$7,529
CombiganBrimonidine Tartrate/Timolol17$6,783
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$6,214
Cyclosporine27$6,030
Brimonidine Tartrate143$5,940
Alphagan PBrimonidine Tartrate18$5,912
Ketorolac Tromethamine206$5,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan, Alphagan P$22$60,681121 claims
Aerie Pharmaceuticals, Inc.Rocklatan$63$9,62317 claims
AlconSimbrinza$63$7,52930 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$25$3,63323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Salem

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →